

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: RFA2/19 - Risk Factors for Atherosclerosis

Dead line: 30.08.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(111) Cholesterol					292						292	284	97%	
Samples and groups	[mmol/L]													
Sample A		3,28	0,12	3,6	292	CVP	3,28	0,017	8%	3,01	3,55	292	288	99%
(1) Abbott		3,32	0,055	1,7	51	0						51		
(12) Beckman Coulter		3,29	0,10	3,1	12	0						12		
(46) Erba Lachema		3,30	0,12	3,5	11	0						11		
(49) BioVendor		3,33	0,19	5,6	8	0						8		
(58) Beckman Coulter (AU)		3,37	0,11	3,2	66	0						66		
(60) Roche		3,19	0,074	2,3	93	0						93		
(149) Siemens (BN, Dimension)		3,24	0,067	2,1	12	0						12		
(177) MINDRAY		3,28	0,059	1,8	7	0						7		
(179) Siemens		3,29	0,10	3,1	24	0						24		
Other					8	0						8		
							2x 5, 1x 18, 1x 32, 1x 121, 1x 166, 2x 178							
Sample B		7,50	0,27	3,7	292	CVP	7,5	0,039	8%	6,9	8,1	292	285	98%
(1) Abbott		7,59	0,14	1,9	51	0						51		
(12) Beckman Coulter		7,52	0,29	3,8	12	0						12		
(46) Erba Lachema		7,48	0,23	3,1	11	0						11		
(49) BioVendor		7,55	0,37	4,9	8	0						8		
(58) Beckman Coulter (AU)		7,76	0,24	3,1	66	0						66		
(60) Roche		7,31	0,18	2,4	93	0						93		
(149) Siemens (BN, Dimension)		7,43	0,22	3,0	12	0						12		
(177) MINDRAY		7,58	0,12	1,6	7	0						7		
(179) Siemens		7,38	0,23	3,2	24	0						24		
Other					8	0						8		
							2x 5, 1x 18, 1x 32, 1x 121, 1x 166, 2x 178							
(112) Triglycerides					292						292	286	98%	
Samples and groups	[mmol/L]													
Sample A		1,02	0,046	4,5	292	CVP	1,02	,0066	15%	0,867	1,18	292	288	99%
(1) Abbott		0,988	0,029	2,9	51	0						51		
(12) Beckman Coulter		0,970	0,076	7,8	11	0						11		
(46) Erba Lachema		1,04	0,066	6,3	14	0						14		
(49) BioVendor		0,985	0,052	5,3	8	0						8		
(58) Beckman Coulter (AU)		1,00	0,028	2,8	64	0						64		
(60) Roche		1,05	0,029	2,8	93	0						93		
(149) Siemens (BN, Dimension)		0,991	0,094	9,5	12	0						12		
(177) MINDRAY		1,01	0,052	5,2	7	0						7		
(179) Siemens		1,04	0,03	2,9	24	0						24		
Other					8	0						8		
							2x 5, 1x 18, 1x 32, 1x 121, 1x 166, 2x 178							
Sample B		2,30	0,069	3,0	292	CVP	2,3	,0099	15%	1,95	2,65	292	290	99%
(1) Abbott		2,28	0,06	2,6	51	0						51		
(12) Beckman Coulter		2,27	0,046	2,0	11	0						11		
(46) Erba Lachema		2,36	0,083	3,5	14	0						14		
(49) BioVendor		2,25	0,074	3,3	8	0						8		
(58) Beckman Coulter (AU)		2,28	0,063	2,8	64	0						64		
(60) Roche		2,33	0,053	2,3	93	0						93		
(149) Siemens (BN, Dimension)		2,31	0,11	4,7	12	0						12		
(177) MINDRAY		2,30	0,11	4,8	7	0						7		
(179) Siemens		2,32	0,052	2,2	24	0						24		
Other					8	0						8		
							2x 5, 1x 18, 1x 32, 1x 121, 1x 166, 2x 178							
(113) Cholesterol HDL					294						294	289	98%	
Samples and groups	[mmol/L]													
Sample A		0,907	0,038	4,2	294	CVP	0,907	,0054	15%	0,77	1,05	294	292	99%
(1) Abbott		0,920	0,03	3,3	51	0						51		
(12) Beckman Coulter		0,916	0,032	3,5	11	0						11		
(46) Erba Lachema		0,906	0,045	5,0	11	0						11		
(49) BioVendor		0,950	0,074	7,8	8	0						8		
(58) Beckman Coulter (AU)		0,883	0,028	3,2	63	0						63		
(60) Roche		0,912	0,028	3,1	91	0						91		
(149) Siemens (BN, Dimension)		0,966	0,041	4,3	12	0						12		
(177) MINDRAY		0,935	0,052	5,6	6	0						6		
(179) Siemens		0,873	0,035	4,0	23	0						23		
Other					18	0						18		
							2x 5, 1x 18, 1x 32, 4x 70, 1x 75, 1x 121, 3x 158, 1x 166, 3x 178, 1x 999							
Sample B		2,05	0,099	4,8	294	CVP	2,05	0,014	15%	1,74	2,36	294	290	99%

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: RFA2/19 - Risk Factors for Atherosclerosis

Dead line: 30.08.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}	
							AV	U _{AV}	D _{max}	LL	UL					
(118) Cholesterol LDL (direct determ.)	[mmol/L]				207							207	205	99%		
----- Samples and groups -----																
Sample B		4,56	0,33	7,3	207		CVP	4,56	0,057	15%	3,87	5,25	207	205	99%	
(1) Abbott		4,81	0,16	3,4	37	0							37			
(12) Beckman Coulter		4,59	0,16	3,6	9	0							9			
(46) Erba Lachema		4,65	0,22	4,8	9	0							9			
(49) BioVendor		4,36	0,36	8,3	6	0							6			
(58) Beckman Coulter (AU)		4,70	0,18	3,8	53	0							53			
(60) Roche		4,21	0,13	3,1	54	0							54			
(149) Siemens (BN, Dimension)		4,60	0,39	8,6	8	0							8			
(179) Siemens		4,82	0,19	4,0	15	0							15			
Other					16	0							16			
								2x 5, 3x 70, 4x 158, 4x 177, 2x 178, 1x 999								
(117) Lipoprotein (a) [g/L]	[g/L]				28							28	26	93%		
----- Samples and groups -----																
Sample A		0,177	0,018	10	28		CVP	0,177	,0085	32%	0,12	0,234	28	27	96%	
(75) Randox		0,180	0,015	8,2	5	0							5			
(179) Siemens		0,185	0,007	4,0	5	0							5			
Other					18	1							18			
								1x 1, 3x 12, 3x 58, 2x 60, 3x 91, 3x 116, 1x 149, 1x 152, 1x 178								
Sample B		0,359	0,032	9,0	28		CVP	0,359	0,015	32%	0,244	0,474	28	26	93%	
(75) Randox		0,362	0,032	8,8	5	0							5			
(179) Siemens		0,354	0,025	6,9	5	0							5			
Other					18	1							18			
								1x 1, 3x 12, 3x 58, 2x 60, 3x 91, 3x 116, 1x 149, 1x 152, 1x 178								
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				25							25	22	88%		
----- Samples and groups -----																
Sample A		32,1	2,7	8,4	25		CVP	32,1	1,3	20%	25,6	38,6	25	23	92%	
(60) Roche		32,2	2,8	8,6	19	0							19			
Other					6	0							6			
								3x 1, 1x 49, 1x 75, 1x 116								
Sample B		75,9	4,1	5,4	25		CVP	75,9	2,0	20%	60,7	91,1	25	23	92%	
(60) Roche		75,5	3,5	4,6	19	0							19			
Other					6	0							6			
								3x 1, 1x 49, 1x 75, 1x 116								

st_kn_p

End of report

Printed: 08.09.2019